Michael Wang, MD, highlights ASH 2025 data showing how continual innovation across targeted agents, cellular and immune ...

Overall, MajesTEC-3 signals a meaningful step forward for combination bispecific therapies in multiple myeloma, while ...

Michael Wang, MD, highlights standout translational studies from ASH 2025 that advance understanding of prognosis and drug ...

Early phase 1 data suggest that in vivo, off-the-shelf CAR T therapy may be feasible in multiple myeloma, offering the promise of faster, less toxic treatment without lymphodepletion while raising ...

Data suggest that remote patient monitoring may support outpatient step-up dosing of bispecific antibodies by enabling earlier CRS detection.

Remote patient monitoring can safely enable outpatient bispecific dosing for selected patients, but older or high-risk individuals may still require closer human oversight and structured support.

Severe alopecia areata may be driven by broader immune activation than previously recognized, according to new research ...

The FDA believes that data on MRD and complete response can expedite new drug delivery compared with long-term survival ...

The bipartisan funding bill prevents a government shutdown, ensuring uninterrupted operations for key agencies, including HHS ...

Although both sodium-glucose cotransporter-2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) ...

The new Horizon1000 partnership aims to deploy AI tools across 1000 clinics to boost care, support health workers, and ...

Two distinct subtypes, U-CLL C1 and U-CLL C2, were identified within IGHV-unmutated chronic lymphocytic leukemia, showing ...